Palvella Secures European Patent for Anhydrous Rapamycin Formulation
Event summary
- Palvella Therapeutics received European Patent No. 3565520 covering anhydrous rapamycin compositions, extending protection to 2038.
- The patent includes claims for QTORIN™ rapamycin's use in treating microcystic lymphatic malformations and venous malformations.
- QTORIN™ rapamycin has Orphan Drug Designation in the EU, potentially offering 10 years of market exclusivity upon approval.
- No approved therapies currently exist in the EU for microcystic lymphatic malformations.
The big picture
Palvella's European patent strengthens its global IP position for QTORIN™ rapamycin, a critical asset in addressing unmet needs in rare skin diseases. The move aligns with broader trends of biopharma companies fortifying exclusivity through patents and regulatory designations to secure long-term market access. With no approved therapies for microcystic lymphatic malformations in the EU, Palvella is positioning itself as a potential first-mover in this niche but growing segment.
What we're watching
- Regulatory Strategy
- How Palvella leverages Orphan Drug Designation to extend market exclusivity in the EU.
- Clinical Pipeline
- The pace at which QTORIN™ rapamycin advances through trials for multiple rare skin diseases.
- IP Protection
- Whether Palvella can maintain durable protection across global markets with its layered exclusivity strategy.